A research team has successfully developed the world’s first nasal organoid-based SARS-CoV-2 neutralizing antibody evaluation platform.
UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment—all without the need to customize treatment for each individual patient.
EPFL researchers have developed a powerful method to generate brain-wide, biologically realistic wiring maps of the mouse brain. Their approach bridges experimental data with mathematical and computational modeling to simulate how neurons connect across the entire brain.
An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialized immune cells.
GE HealthCare (Nasdaq: GEHC)+
today announced the launch of Vivid Pioneer, its newest, most advanced cardiovascular ultrasound system.
Abbott (NYSE: ABT)+
announced today that it received CE mark for an expanded indication for its Navitor TAVI system.
The NeuViz P10 uses a cadmium zinc telluride detector to directly convert X-ray photons, thereby eliminating light conversion.
A multi-institutional clinical trial conducted at the UNC Lineberger Comprehensive Cancer Center and 21 other U.S. sites found that a single administration of autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. This finding is significant, as many of these patients had previously undergone multiple treatments without success.
Biomedical engineers at Duke University have successfully conducted experiments to treat damage caused by heart attacks in nonhuman primates using gene therapy for the first time.
Tuberculosis has been a scourge upon humanity throughout history. In killing more than a million each year worldwide, it remains the leading cause of death from a single infectious pathogen.